1
|
Ravan M, Noroozi A, Gediya H, James Basco K, Hasey G. Using deep learning and pretreatment EEG to predict response to sertraline, bupropion, and placebo. Clin Neurophysiol 2024; 167:198-208. [PMID: 39332081 DOI: 10.1016/j.clinph.2024.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 07/08/2024] [Accepted: 09/04/2024] [Indexed: 09/29/2024]
Abstract
OBJECTIVE Predicting an individual's response to antidepressant medication remains one of the most challenging tasks in the treatment of major depressive disorder (MDD). Our objective was to use the large EMBARC study database to develop an electroencephalography (EEG)-based method to predict response to antidepressant treatment. METHODS Pre-treatment EEG data were collected from study participants treated with either sertraline (N = 105), placebo (N = 119), or bupropion (N = 35). After preprocessing, the robust exact low-resolution electromagnetic tomography (ReLORETA) brain source localization method was used to reconstruct the source signals in 54 brain regions. Connectivity between regions was determined using symbolic transfer entropy (STE). A convolutional neural network (CNN) classified participants as responders or non-responders to each treatment. RESULTS Classification accuracy was 91.0%, 95.4%, and 86.8% for sertraline, placebo, and bupropion, respectively. The most highly predictive features were connectivity between i) the anterior cingulate cortex and superior parietal lobule (alpha frequency), ii) the anterior cingulate cortex and orbitofrontal area (beta frequency), and iii) the orbitofrontal area and anterior cingulate cortex (gamma frequency). CONCLUSION CNN analysis of EEG connectivity may accurately predict response to sertraline, bupropion, and placebo. SIGNIFICANCE The suggested method may offer clinicians an accessible and cost-effective tool for speedy treatment and helps pharmaceutical firms to test new antidepressants efficiently.
Collapse
Affiliation(s)
- Marman Ravan
- Department of Electrical and Computer Engineering, New York Institute of Technology, New York, NY, USA.
| | - Amin Noroozi
- School of Engineering, Computing & Mathematical Sciences, University of Wolverhampton, Wolverhampton, UK
| | - Harshil Gediya
- Department of Computer Science, New York Institute of Technology, New York, NY, USA
| | - Kennette James Basco
- Department of Computer Science, New York Institute of Technology, New York, NY, USA
| | - Gary Hasey
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
2
|
Karvelis P, Charlton CE, Allohverdi SG, Bedford P, Hauke DJ, Diaconescu AO. Computational approaches to treatment response prediction in major depression using brain activity and behavioral data: A systematic review. Netw Neurosci 2022; 6:1066-1103. [PMID: 38800454 PMCID: PMC11117101 DOI: 10.1162/netn_a_00233] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Accepted: 01/14/2022] [Indexed: 05/29/2024] Open
Abstract
Major depressive disorder is a heterogeneous diagnostic category with multiple available treatments. With the goal of optimizing treatment selection, researchers are developing computational models that attempt to predict treatment response based on various pretreatment measures. In this paper, we review studies that use brain activity data to predict treatment response. Our aim is to highlight and clarify important methodological differences between various studies that relate to the incorporation of domain knowledge, specifically within two approaches delineated as data-driven and theory-driven. We argue that theory-driven generative modeling, which explicitly models information processing in the brain and thus can capture disease mechanisms, is a promising emerging approach that is only beginning to be utilized in treatment response prediction. The predictors extracted via such models could improve interpretability, which is critical for clinical decision-making. We also identify several methodological limitations across the reviewed studies and provide suggestions for addressing them. Namely, we consider problems with dichotomizing treatment outcomes, the importance of investigating more than one treatment in a given study for differential treatment response predictions, the need for a patient-centered approach for defining treatment outcomes, and finally, the use of internal and external validation methods for improving model generalizability.
Collapse
Affiliation(s)
- Povilas Karvelis
- Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - Colleen E. Charlton
- Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - Shona G. Allohverdi
- Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - Peter Bedford
- Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
| | - Daniel J. Hauke
- Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
- Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
- Department of Mathematics and Computer Science, University of Basel, Basel, Switzerland
| | - Andreea O. Diaconescu
- Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
- University of Toronto, Department of Psychiatry, Toronto, ON, Canada
- Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
- Department of Psychology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
3
|
Watts D, Pulice RF, Reilly J, Brunoni AR, Kapczinski F, Passos IC. Predicting treatment response using EEG in major depressive disorder: A machine-learning meta-analysis. Transl Psychiatry 2022; 12:332. [PMID: 35961967 PMCID: PMC9374666 DOI: 10.1038/s41398-022-02064-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 06/27/2022] [Accepted: 07/06/2022] [Indexed: 11/09/2022] Open
Abstract
Selecting a course of treatment in psychiatry remains a trial-and-error process, and this long-standing clinical challenge has prompted an increased focus on predictive models of treatment response using machine learning techniques. Electroencephalography (EEG) represents a cost-effective and scalable potential measure to predict treatment response to major depressive disorder. We performed separate meta-analyses to determine the ability of models to distinguish between responders and non-responders using EEG across treatments, as well as a performed subgroup analysis of response to transcranial magnetic stimulation (rTMS), and antidepressants (Registration Number: CRD42021257477) in Major Depressive Disorder by searching PubMed, Scopus, and Web of Science for articles published between January 1960 and February 2022. We included 15 studies that predicted treatment responses among patients with major depressive disorder using machine-learning techniques. Within a random-effects model with a restricted maximum likelihood estimator comprising 758 patients, the pooled accuracy across studies was 83.93% (95% CI: 78.90-89.29), with an Area-Under-the-Curve (AUC) of 0.850 (95% CI: 0.747-0.890), and partial AUC of 0.779. The average sensitivity and specificity across models were 77.96% (95% CI: 60.05-88.70), and 84.60% (95% CI: 67.89-92.39), respectively. In a subgroup analysis, greater performance was observed in predicting response to rTMS (Pooled accuracy: 85.70% (95% CI: 77.45-94.83), Area-Under-the-Curve (AUC): 0.928, partial AUC: 0.844), relative to antidepressants (Pooled accuracy: 81.41% (95% CI: 77.45-94.83, AUC: 0.895, pAUC: 0.821). Furthermore, across all meta-analyses, the specificity (true negatives) of EEG models was greater than the sensitivity (true positives), suggesting that EEG models thus far better identify non-responders than responders to treatment in MDD. Studies varied widely in important features across models, although relevant features included absolute and relative power in frontal and temporal electrodes, measures of connectivity, and asymmetry across hemispheres. Predictive models of treatment response using EEG hold promise in major depressive disorder, although there is a need for prospective model validation in independent datasets, and a greater emphasis on replicating physiological markers. Crucially, standardization in cut-off values and clinical scales for defining clinical response and non-response will aid in the reproducibility of findings and the clinical utility of predictive models. Furthermore, several models thus far have used data from open-label trials with small sample sizes and evaluated performance in the absence of training and testing sets, which increases the risk of statistical overfitting. Large consortium studies are required to establish predictive signatures of treatment response using EEG, and better elucidate the replicability of specific markers. Additionally, it is speculated that greater performance was observed in rTMS models, since EEG is assessing neural networks more likely to be directly targeted by rTMS, comprising electrical activity primarily near the surface of the cortex. Prospectively, there is a need for models that examine the comparative effectiveness of multiple treatments across the same patients. However, this will require a thoughtful consideration towards cumulative treatment effects, and whether washout periods between treatments should be utilised. Regardless, longitudinal cross-over trials comparing multiple treatments across the same group of patients will be an important prerequisite step to both facilitate precision psychiatry and identify generalizable physiological predictors of response between and across treatment options.
Collapse
Affiliation(s)
- Devon Watts
- grid.25073.330000 0004 1936 8227Neuroscience Graduate Program, McMaster University, Hamilton, Canada
| | - Rafaela Fernandes Pulice
- grid.8532.c0000 0001 2200 7498School of Medicine, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS Brasil ,grid.414449.80000 0001 0125 3761Laboratório de Molecular Psychiatry, Centro de Pesquisa Experimental (CPE) and Centro de Pesquisa Clínica (CPC), Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS Brasil
| | - Jim Reilly
- grid.25073.330000 0004 1936 8227Department of Electrical & Computer Engineering, McMaster University, Hamilton, ON Canada
| | - Andre R. Brunoni
- grid.11899.380000 0004 1937 0722Service of Interdisciplinary Neuromodulation, Laboratory of Neurosciences (LIM-27), Institute of Psychiatry, University of São Paulo, São Paulo, Brasil ,grid.11899.380000 0004 1937 0722Departamento de Clínica Médica, Faculdade de Medicina da USP, São Paulo, Brasil
| | - Flávio Kapczinski
- grid.25073.330000 0004 1936 8227Neuroscience Graduate Program, McMaster University, Hamilton, Canada ,grid.414449.80000 0001 0125 3761Laboratório de Molecular Psychiatry, Centro de Pesquisa Experimental (CPE) and Centro de Pesquisa Clínica (CPC), Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS Brasil ,Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Porto Alegre, RS Brasil ,grid.25073.330000 0004 1936 8227Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON Canada
| | - Ives Cavalcante Passos
- School of Medicine, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, RS, Brasil. .,Laboratório de Molecular Psychiatry, Centro de Pesquisa Experimental (CPE) and Centro de Pesquisa Clínica (CPC), Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brasil.
| |
Collapse
|
4
|
Campanella S, Arikan K, Babiloni C, Balconi M, Bertollo M, Betti V, Bianchi L, Brunovsky M, Buttinelli C, Comani S, Di Lorenzo G, Dumalin D, Escera C, Fallgatter A, Fisher D, Giordano GM, Guntekin B, Imperatori C, Ishii R, Kajosch H, Kiang M, López-Caneda E, Missonnier P, Mucci A, Olbrich S, Otte G, Perrottelli A, Pizzuti A, Pinal D, Salisbury D, Tang Y, Tisei P, Wang J, Winkler I, Yuan J, Pogarell O. Special Report on the Impact of the COVID-19 Pandemic on Clinical EEG and Research and Consensus Recommendations for the Safe Use of EEG. Clin EEG Neurosci 2021; 52:3-28. [PMID: 32975150 PMCID: PMC8121213 DOI: 10.1177/1550059420954054] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
INTRODUCTION The global COVID-19 pandemic has affected the economy, daily life, and mental/physical health. The latter includes the use of electroencephalography (EEG) in clinical practice and research. We report a survey of the impact of COVID-19 on the use of clinical EEG in practice and research in several countries, and the recommendations of an international panel of experts for the safe application of EEG during and after this pandemic. METHODS Fifteen clinicians from 8 different countries and 25 researchers from 13 different countries reported the impact of COVID-19 on their EEG activities, the procedures implemented in response to the COVID-19 pandemic, and precautions planned or already implemented during the reopening of EEG activities. RESULTS Of the 15 clinical centers responding, 11 reported a total stoppage of all EEG activities, while 4 reduced the number of tests per day. In research settings, all 25 laboratories reported a complete stoppage of activity, with 7 laboratories reopening to some extent since initial closure. In both settings, recommended precautions for restarting or continuing EEG recording included strict hygienic rules, social distance, and assessment for infection symptoms among staff and patients/participants. CONCLUSIONS The COVID-19 pandemic interfered with the use of EEG recordings in clinical practice and even more in clinical research. We suggest updated best practices to allow safe EEG recordings in both research and clinical settings. The continued use of EEG is important in those with psychiatric diseases, particularly in times of social alarm such as the COVID-19 pandemic.
Collapse
Affiliation(s)
- Salvatore Campanella
- Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Belgium
| | - Kemal Arikan
- Kemal Arıkan Psychiatry Clinic, Istanbul, Turkey
| | - Claudio Babiloni
- Department of Physiology and Pharmacology "Erspamer", Sapienza University of Rome, Italy.,San Raffaele Cassino, Cassino (FR), Italy
| | - Michela Balconi
- Research Unit in Affective and Social Neuroscience, Department of Psychology, Catholic University of Milan, Milan, Italy
| | - Maurizio Bertollo
- BIND-Behavioral Imaging and Neural Dynamics Center, Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy
| | - Viviana Betti
- Department of Psychology, Sapienza University of Rome, Fondazione Santa Lucia, Rome, Italy
| | - Luigi Bianchi
- Dipartimento di Ingegneria Civile e Ingegneria Informatica (DICII), University of Rome Tor Vergata, Rome, Italy
| | - Martin Brunovsky
- National Institute of Mental Health, Klecany Czech Republic.,Third Medical Faculty, Charles University, Prague, Czech Republic
| | - Carla Buttinelli
- Department of Neurosciences, Public Health and Sense Organs (NESMOS), Sapienza University of Rome, Rome, Italy
| | - Silvia Comani
- BIND-Behavioral Imaging and Neural Dynamics Center, Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy
| | - Giorgio Di Lorenzo
- Laboratory of Psychophysiology and Cognitive Neuroscience, Chair of Psychiatry, Department of Systems Medicine, School of Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.,IRCCS Fondazione Santa Lucia, Rome, Italy
| | - Daniel Dumalin
- AZ Sint-Jan Brugge-Oostende AV, Campus Henri Serruys, Lab of Neurophysiology, Department Neurology-Psychiatry, Ostend, Belgium
| | - Carles Escera
- Brainlab-Cognitive Neuroscience Research Group, Department of Clinical Psychology and Psychobiology, Institute of Neurosciences, University of Barcelona, Barcelona, Spain
| | - Andreas Fallgatter
- Department of Psychiatry, University of Tübingen, Germany; LEAD Graduate School and Training Center, Tübingen, Germany.,German Center for Neurodegenerative Diseases DZNE, Tübingen, Germany
| | - Derek Fisher
- Department of Psychology, Mount Saint Vincent University, and Department of Psychiatry, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
| | | | - Bahar Guntekin
- Department of Biophysics, School of Medicine, Istanbul Medipol University, Istanbul, Turkey
| | - Claudio Imperatori
- Cognitive and Clinical Psychology Laboratory, Department of Human Science, European University of Rome, Rome, Italy
| | - Ryouhei Ishii
- Department of Psychiatry Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hendrik Kajosch
- Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Belgium
| | - Michael Kiang
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Eduardo López-Caneda
- Psychological Neuroscience Laboratory, Center for Research in Psychology, School of Psychology, University of Minho, Braga, Portugal
| | - Pascal Missonnier
- Mental Health Network Fribourg (RFSM), Sector of Psychiatry and Psychotherapy for Adults, Marsens, Switzerland
| | - Armida Mucci
- Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Sebastian Olbrich
- Psychotherapy and Psychosomatics, Department for Psychiatry, University Hospital Zurich, Zurich, Switzerland
| | | | - Andrea Perrottelli
- Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Alessandra Pizzuti
- Department of Psychology, Sapienza University of Rome, Fondazione Santa Lucia, Rome, Italy
| | - Diego Pinal
- Psychological Neuroscience Laboratory, Center for Research in Psychology, School of Psychology, University of Minho, Braga, Portugal
| | - Dean Salisbury
- Clinical Neurophysiology Research Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Yingying Tang
- Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Paolo Tisei
- Department of Neurosciences, Public Health and Sense Organs (NESMOS), Sapienza University of Rome, Rome, Italy
| | - Jijun Wang
- Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Istvan Winkler
- Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Budapest, Hungary
| | - Jiajin Yuan
- Institute of Brain and Psychological Sciences, Sichuan Normal University, Chengdu, China
| | - Oliver Pogarell
- Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|